OTC · RTGN
Healthcare · Medical - Devices
$3.99
Up+$0.00 (+0.00%)
Updated Oct 12, 2026, 10:53 AM
SID Score
—
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · RTGN
1M range · 0 trading sessions · Daily adjusted prices
RTGN does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
The latest Smart Investors Daily articles mentioning RTGN.
Company
Market Activity
Research & News
RTGN research
Company profile and research snapshot.
RETINALGENIX TECHNOLOGIES
Visit company websiteConsensus and target data currently published for this company.
No generated briefing is available yet.
Finnhub · Apr 15, 2026
RetinalGenix Technologies Inc. reported earnings results for the full year ended December 31, 2025. For the full year, the company reported net loss was USD 2.43 million compared to USD 4.32 million a...
GlobeNewswire Inc. · Dec 9, 2025
RetinalGenix Technologies has hired M. Cory Zwerling as its chief financial officer and interim chief operating officer, effective January 1, 2026. Zwerling brings over three decades of global experience in healthcare, finance, and operations to help the company transition from R&D to early commercial operations.
globenewswire.com · Oct 16, 2025
APOLLO BEACH, Fla. , Oct. 16, 2025 (GLOBE NEWSWIRE) -- RetinalGenix Technologies Inc. [OTCQB: RTGN] ("RetinalGenix" or the "Company"), a company developing ultra-high-resolution retinal imaging technology, today announced it has engaged Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, to help identify novel biomarkers that enable earlier detection and more precise monitoring of systemic, neurodegenerative, and retinal diseases.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning RTGN.
No results
No recent SID articles mention RTGN.
